Back to search

Article

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

2025-09-11

Abstract excerpt

<h4>ABSTRACT</h4> Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive subtype of prostate cancer (PC) without curative treatments. Antibody-drug conjugates (ADCs) emerged as promising cancer therapeutics that selectively deliver cytotoxic agents (payloads) to the tumors. Although ADCs have been successfully applied in the treatment of hematological and solid tumors, ADC monotherapy has not de...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
09a4dea0-34a4-57f2-b2eb-c6d3284bd272
DOI
10.1101/2025.09.05.674562
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerDOI 10.1101/2025.09.05.674562
Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancerSemantic proximity
Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory PropertiesSemantic proximity
Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancerSemantic proximity
CD46 targeted <sup>212</sup> Pb alpha particle radioimmunotherapy for prostate cancer treatmentSemantic proximity
Antibody-mediated co-delivery of programmable drug combinationsSemantic proximity
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificitySemantic proximity
PSMA-CAR-T Cells for Metastatic Castration-Resistant Prostate Cancer: An Integrated Framework for Translational OptimizationSemantic proximity
ITC-6102RO, A Novel B7-H3 Antibody-Drug Conjugate, Exhibits Potent Therapeutic Effects against B7-H3 Expressing Solid TumorsSemantic proximity
Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)Semantic proximity
Select a neighboring publication to make it the new centre.